Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Patient Engagement Leadership Team

Patient Engagement Leadership Team

We work with today's informed and empowered patients to ensure our solutions are designed for and reach the people who need them.

Patient Engagement is everyone's responsibility at Janssen, exemplified by support from the highest levels of our organization. Learn more about our integrated, cross-functional Patient Engagement Leadership Team.  

Patient Engagement

Martin Freeman, Untitled



Katherine Capperella is Global Head, Patient Engagement Leader at Janssen.  In this role, Katherine leads a cross-functional team responsible for developing and driving patient engagement strategy and measuring progress over time. She and her team are focused on leading Janssen to incorporate direct patient voice early and throughout the entire product lifecycle, beginning with disease area strategies and including target product profiles, formulations, clinical trials and post-marketing activities.

Katherine has more than 20 years of experience at Johnson & Johnson in roles of increasing responsibility. Previously, Katherine served as global commercial vice president for Janssen’s Active Pharmaceutical Ingredients (API) business developing pharmaceutical ingredients for pain. Prior to that, Katherine led a cross-functional team responsible for commercial assessments of licensing and acquisition opportunities for Janssen neuroscience. Katherine began her career in women’s health and has demonstrated success in launch, turnaround and mature businesses in a variety of disease areas.

Katherine holds a Bachelor of Science in Business/Marketing from the Kelley School of Business.

Katherine Capperella

Global Head
Patient Engagement Leader



Jill E. Abell, M.PH., Ph.D. is the Scientific Patient Engagement Lead, Center for Medical Excellence for Janssen Scientific Affairs. In her role, she focuses on facilitating a patient-inspired approach in scientific research incorporating the patient voice and generating meaningful insight and innovative solutions to advance capabilities and support products at launch and on the market. She leads her team in advancing new capabilities, methodological strategies and pragmatic approaches to research implementation that advance real world evaluations.

Prior to joining Janssen, Jill was Senior Director, Clinical Effectiveness and Safety at GlaxoSmithKline where she provided leadership and influential collaborative interactions for the advancement of clinical effectiveness evaluations in populations and individuals. There she also served as an epidemiologist, giving strategic direction and emphasizing innovative designs for pragmatic trials, international observational studies, web-based studies, over-the-counter studies, and composite endpoint development. Jill was also on faculty as an Adjunct Assistant Professor in Clinical Epidemiology and Evaluative Sciences at Weill Cornell Graduate School of Medical Sciences.

Jill received a Master of Public Health degree in Epidemiology from Emory University and a Doctor of Philosophy (Ph.D.) degree in Epidemiology from the Medical University of South Carolina, where she was supported by an American Heart Association Pre-Doctoral Fellowship.

Jill E. Abell, MPH, Ph.D.




Carrie Corboy is the Senior Director, Standards & Execution Excellence at Janssen Pharmaceutical Companies of Johnson & Johnson. She currently supports the Janssen global commercial organization including capturing performance metrics in patient engagement and establishing a framework for complying with company policies and global requirements while encouraging engagement with patients. Carrie’s  career spans over 20 years with experience in the biopharmaceutical industry in the areas of pharmacovigilance, regulatory affairs, regulatory policy, compliance and clinical development.

Carrie started her career at Johnson & Johnson Pharmaceutical Research & Development in 2001, serving in roles as Director of Standards & Execution Excellence and Senior Scientist of Aggregate Reporting. A licensed pharmacist, prior to joining Johnson & Johnson, she worked in pharmacist and directorial roles in organizations including Advanced Biologics and Bristol Myers Squibb.  She is an active member of the New Jersey Pharmacists Association (NJPhA).

Carrie holds her Bachelor of Science degree in Pharmacy from Rutgers University-New Brunswick, New Jersey, and her Doctor of Pharmacy degree from University of the Sciences in Philadelphia, Pennsylvania.

Carrie Corboy, RPh, PharmD

Senior Director
Standards & Execution Excellence



Daniel De Schryver is Patient Engagement & Advocacy Lead for Europe, Middle East and Africa (EMEA).

In this function, Daniel is part of a global multi-functional leadership team that helps the company to engage with patients in a systematic way and helps to build partnerships in developing solutions that better meet the existing needs.  He also leads a team in the EMEA region who play a crucial role in working towards a more collaborative approach in innovation.

Daniel joined Johnson & Johnson in 2001 as Director, Corporate Communications. In that function, he initially worked in the field of oncology. In 2006 he joined the Janssen teams working in Infectious Diseases where he helped to maintain and enhance the company’s relationships with the HIV Patient Community.  Later, he built the external relationships in the field of Hepatitis C, before becoming the Global Therapeutic Area Communications Leader Infectious Diseases and Vaccines.  In this function he developed world wide strategic communications and public affairs programs about infectious diseases and global public health.

Before joining Johnson & Johnson, he worked at Burson-Marsteller as corporate communications consultant. Daniel started his communications career in the car industry for several years, he joined the non-profit sector and became country manager for Médecins Sans Frontières in Bosnia, Croatia and Angola.  Back in Europe, he headed the Communications department for the organization.

Daniel has a Master in Romance Philology (Literature) and he started his career as a teacher.  His personal interests are contemporary art and architecture, politics and meeting people.

Daniel De Schryver

Patient Engagement & Advocacy Lead
Middle-East and Africa



Joaquin Garcia-Lopez is Director, Market Research Excellence for the Global Commercial Strategy Organization (GCSO) at Janssen. In this role, Joaquin is responsible for driving functional excellence in market research across the global team, bringing together analytics professionals in GCSO and regional commercial roles to accelerate best practice sharing regarding market research methodologies and implementation. He partners with market researchers within GCSO Therapy Area teams to drive cutting-edge research to support development decisions for compounds in Janssen’s R&D pipeline. His focus includes providing guidance on reliable methods for unearthing rich patient emotional and rational insights to fuel asset strategies throughout the disease continuum and product life cycles.

Joaquin joined Janssen in 2015 as Associate Director of Global Market Research for the Neurodegeneration Disease Area Stronghold within GCSO. In this role, Joaquin was responsible for the generation of actionable customer analytics and insights to help the Neurodegeneration team identify ways to build and maximize the value of its global pipeline assets. He was the market research lead on a wide range of programs related to the future management of preclinical Alzheimer’s disease and served as commercial lead for the alpha-2C inhibitor asset and atabecestat’s EARLY trial communications program.

In his previous role, Joaquin was Vice President of healthcare research at ORC International, a market research and business intelligence firm. In this role, he worked with a broad portfolio of pharmaceutical clients and led consultative market analytics meeting a range of business needs such as new product development, lifecycle management strategies and various drug launches.  Joaquin started his pharmaceutical career as a bench biomedical engineer at Forticell Bioscience’s process development group, where he worked on the development and launch of novel cell therapies and advanced biomaterials.

Joaquin graduated from Columbia University with both an Master of Science in Technology Management and a Bachelor of Science in Biomedical Engineering and holds a B.A. in Mathematics from Fordham University.

Joaquin Garcia-Lopez

Market Research Excellence
Global Commercial Strategy Organization



Tammy is the Senior Director of Clinical Innovation at Janssen. She is a pharmaceutical executive with more than 20 years of experience, and her expertise includes strategic and operational delivery across clinical development, regulatory affairs, and healthcare innovation. She has a passion for leading large, global teams and skilled at developing others.

She currently leads the creation and scaling of new operational approaches and technologies into clinical research with the goals of expediting drug development, reducing overall costs, and improving patient and site experiences.

Through the design and conduct of novel trial models and demonstration projects, Tammy is responsible for the overall performance & portfolio optimization of Janssen Clinical Innovation, generating data and knowledge about the feasibility, impact, and value of new capabilities. 

Tammy previously served as Head of Central Clinical Planning & Solutions at Bristol Myers Squibb where she led a global team that expedited clinical trials through application of external insights, analytics and digital technology resulting in best-practice clinical trial experiences for patients, care partners, and sites. She launched her career at the organization, holding various positions in clinical development including Group Director of Global Regulatory Documentation to oversee regulatory documentation and submission strategy for oncology and immunology therapeutic areas. 

Tammy holds a Bachelor of Science degree from Bucknell University in Biochemistry and her Master of Science in Clinical Pharmacology from Thomas Jefferson University.   

Tammy Guld

Senior Director
Clinical Innovation



Beverly Harrison is responsible for leading the Patient Support Group reporting directly to the Chief Medical Officer at Janssen R&D, the research arm of Johnson & Johnson, focusing on developing strategies to understand and support the needs of patients by working with internal and external stakeholders, including a special focus on engaging patient advocacy organizations.

She is a research, development, and nonprofit patient advocacy professional with more than 20 years of leadership experience integrating team efforts across functions with increasingly high levels of responsibility for impacting the policies and performance of pharmaceutical, CRO and nonprofit organizations.

Beverly holds a Bachelor of Science in Political Science degree from William & Mary, Williamsburg, Virgina.

Beverly L. Harrison

Senior Director
Patient Support



Rochelle Kleinberg is the Director for Healthcare Solutions at Johnson & Johnson Design. She brings significant design and strategic experience to the development of holistic, patient-centered solutions that empower people with health conditions to better manage therapy and enable improved health outcomes.

Rochelle joined Johnson & Johnson in 2008, first as Design Strategy Director, then as Industrial Design Director before taking on her current role focusing on J&J Design’s collaboration with Janssen. A champion for human-centered design and patient engagement, she works with numerous internal and external stakeholders to develop and realize products and experiences that address the unmet needs of patients and all those involved in their care.

Prior to joining Johnson & Johnson, Rochelle was the Creative Director for North America for Dyson Inc., Executive Director of Global Package Design for Clinique Laboratories LLC, part of the Estée Lauder Companies, and Senior Designer at TKO Design in London working on a diverse range of projects for clients such as Sony, Honda, Sanyo, Hasbro and Procter & Gamble.

She holds a Bachelor of Architecture degree from Carnegie Mellon University and a Master of Arts in Industrial Design from Central Saint Martins in London.

Rochelle Kleinberg

Healthcare Solutions



Pauline McNulty is Vice President, Patient Reported Outcomes, Global Market Access in the Global Commercial Strategy Organization at Janssen.  In this role, she is responsible for ensuring the patient’s perspective is appropriately incorporated into global drug development programs through measurement of Patient Reported Outcomes (PROs). In addition, she leads several internal programs related to talent development in the global market access community at Janssen.

Pauline joined Johnson & Johnson in 1994 as a Director in the Health Economics department. Since that time, she has held positions of broad and increasing responsibility, including Vice President Health Economics, when she was responsible for health economics for all products in development, and Vice President Health Economics & Pricing when she was responsible for market access for products in the Internal Medicine portfolio.

Previously, Pauline worked at Schering-Plough, where she was Director Pharmacoeconomics for Respiratory and Cardiovascular products in development as well as those already on the market. Prior to joining the pharmaceutical industry, she worked for a healthcare research and consulting company, SysteMetrics, in Santa Barbara, California. 

Pauline has been involved in several external initiatives and forums that relate to patient representation and outcomes. In 2009-2010, Pauline served as a member of the Steering Committee for the National Quality Forum’s (NQF) National Voluntary Consensus Standards for Patient Outcomes. Currently, she is a member of the PhRMA Patient Focused Drug Development Work Group and the National Health Council’s Patient Engagement Work Group. Within Janssen, she is a member of the Global Patient Engagement Team, whose mission is to partner with patients and caregivers from an early stage of drug development to maintain an ongoing dialogue to develop solutions that better meet their needs

Pauline received her Ph.D. in experimental psychology from the University of California, Santa Barbara.  She has an Master of Science in Experimental Psychology and a Bachelor of Science in Science from University College Dublin. She has published several articles related to health economics and patient reported outcomes and the patient’s perspective in drug treatment. From 2009- 2011, Pauline participated in Johnson & Johnson’s Health Policy Excellence Program through the Jefferson School of Population Health.

Pauline McNulty, Ph.D.

Vice President
Patient Reported Outcomes, Global Market Access
Global Commercial Strategy Organization



Michael Mitchell is the Communication Leader, Global Commercial Strategy Organization (GCSO) and R&D Executive Support within the Janssen R&D Communication team.

Michael is responsible for building and leading the strategic planning, development and implementation of integrated external and internal communication for GCSO, Janssen’s Patient Engagement strategy, as well as providing R&D executive communication support. He has also been instrumental in the launch of Janssen One, the long-term global strategy for the company.

Michael joined Johnson & Johnson in October of 2016. Previously, he was with The Medicines Company for 14 years in a variety of roles of increasing responsibility, including as Value Development Lead for Kengreal (cangrelor), where he was responsible for economics and reimbursement, and market access to prepare for launch of Kengreal in the United States. Prior to that position, Michael was Head of Global Communications where he led investor, employee, and product communication. Michael also held the position of Executive Director of Corporate Affairs and Critical Care Business Manager for Northern New Jersey.

Prior to joining The Medicines Company, Michael advised biotechnology clients at Feinstein Kean Healthcare and started his career at Edelman Healthcare.

He currently serves on the Board of the First Tee of Greater Trenton. Michael also served on the Executive Committee for the American Heart Association (AHA) Morris County Heart Walk, 5K run from 2010 through 2014.

Michael earned his Master’s in Business Administration from Rutgers, The State University of New Jersey and his Bachelor of Science in Health Policy and Management from Providence College.

Michael Mitchell

Communication Leader
Global Commercial Strategy Organization



Heidi Müller is Director, Patient Engagement Strategy. This global role resides within the Clinical Insights and Experience (CI&E) department, within the Global Clinical Development Organization (GCDO), focusing on the coordination of Ph l-IV clinical trials for pharmaceutical products.

In this role, Heidi coordinates the CI&E internal and external communication strategies, and she ensures a measurement framework to demonstrate both Return on Engagement and the impact of our communications. Also, she co-leads a change management process to embed Patient & Investigator centricity in everything we do - in line with our CREDO. As a member of the Patient Engagement Leadership Team (PELT), Heidi represents GCDO in ensuring a systematic company approach on Patient Engagement.

Heidi is a nurse by training and holds a Master degree in Healthcare Management. She started her career as a nurse at an intensive care unit, after which she joined clinical research in 1993. Since then she held various clinical operational roles, both in pharma and Clinical Research Organizations (CROs). She joined Tibotec (later acquired by Johnson & Johnson) in 2002, where she spent 16 years in Infectious Diseases & Vaccines, prior to assuming this global, cross therapeutic area role. Heidi’s professional passions relate to patient-centricity and stakeholder engagement in clinical research.

Heidi Müller

Patient Engagement Strategy